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The burden of healthcare-associated Clostridium difficile infection in a non-
metropolitan setting 
Abstract 
Objective: Healthcare-associated Clostridium difficile infection (HCA-CDI) remains a major cause of 
morbidity and mortality in industrialized countries. However, few data exist on the burden of HCA-CDI in 
multi-site non-metropolitan settings. This study examined the introduction of an antimicrobial 
stewardship programme (ASP) in relation to HCA-CDI rates, and the effect of HCA-CDI on length of stay 
(LOS) and hospital costs. 
Methods: A comparative before-and-after intervention study of patients aged ≥16 years with HCA-CDI 
from December 2010 to April 2016 across the nine hospitals of a non-metropolitan health district in New 
South Wales, Australia was undertaken. The intervention comprised a multi-site ASP supported by a 
clinical decision support system, with subsequent introduction of email feedback of HCA-CDI cases to 
admitting medical officers. 
Main outcome measures: HCA-CDI rates, comparative LOS and hospital costs, prior use of antimicrobials 
and proton pump inhibitors, and appropriateness of CDI treatment. 
Results: HCA-CDI rates rose from 3.07 to 4.60 cases per 10,000 occupied bed-days pre-intervention, and 
remained stable at 4 cases per 10,000 occupied bed-days post-intervention (P = 0.24). Median LOS (17 vs 
six days; P < 0.01) and hospital costs (AU$19,222 vs $7861; P < 0.01) were significantly greater for HCA-
CDI cases (N = 91) than for matched controls (N = 172). Half of the patients with severe HCA-CDI (4/8) 
did not receive initial appropriate treatment (oral vancomycin). 
Conclusions: HCA-CDI placed a significant burden on the regional and rural health service through 
increased LOS and hospital costs. Interventions targeting HCA-CDI could be employed to consolidate the 
effects of ASPs. 
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Clostridium difficile infection is a major cause of healthcare associated diarrhoea in 
industrialised countries and is associated with considerable morbidity and mortality. 
No data exist on the burden of healthcare associated Clostridium difficile infection 
(HCA-CDI) in multisite non-metropolitan settings. This study examined the 
introduction of an antimicrobial stewardship program (ASP) in relation to HCA-CDI 
rates and the effect of HCA-CDI on length of stay (LOS) and hospital costs. 
Methods 
A comparative before-and-after intervention study of patients aged 16 years and over 
with HCA-CDI from December 2010 to April 2016 across the nine hospitals of a 
regional and rural health district in New South Wales, Australia. The intervention 
consisted of a multisite ASP supported by a clinical decision support system, with 
subsequent introduction of email feedback of HCA-CDI cases to admitting medical 
officers. Main outcome measures: HCA-CDI rates; comparative LOS and hospital 
costs; prior antimicrobial and proton-pump inhibitor use; appropriateness of CDI 
treatment. 
Results 
HCA-CDI rates were stable at four cases per 10,000 occupied bed days following the 
intervention. Median LOS (17 vs. 6 days, P<0.01) and hospital costs (AU$19,222 vs. 
$7,861, P <0.01) were significantly greater for HCA-CDI cases (N=91) than for 
matched controls (N=172). Half of the patients with severe HCA-CDI (4/8) did not 




HCA-CDI placed a significant burden on our regional and rural health service through 
increased LOS and hospital costs. Interventions targeting HCA-CDI could be 
employed to consolidate the effects of ASPs. 
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Clostridium difficile infection (CDI) is a major cause of healthcare associated 
diarrhoea in industrialised countries and is associated with considerable morbidity and 
mortality.1 In Australia, the annual incidence of hospital-identified CDI was 4.03 
cases/10,000 patient days in 2012.2 Risk is increased by antimicrobial use and/or 
immunosuppression.3 Other putative risk factors include gastrointestinal surgery, 
gastric acid-suppressive therapy and prolonged hospital stay.3  
 
Healthcare associated Clostridium difficile infection (HCA-CDI) has been associated 
with increased length of stay (LOS), additional costs from hospitalisation4 and 
antimicrobial treatment,3 and indirect costs such as productivity losses.5  
 
Most antimicrobials have been related to CDI, with lincosamides (e.g. clindamycin), 
third generation cephalosporins (e.g. ceftriaxone), and broad-spectrum penicillins 
(e.g. amoxicillin/clavulanic acid) showing strong associations.6 Fluoroquinolones 
have been particularly associated with the hypervirulent NAP1/027 strain.7 There is 
probable association between proton pump inhibitor (PPI) use and CDI, with the 
combination of PPIs and antimicrobials carrying a greater risk than either alone.8 
 
Antimicrobial stewardship programs (ASPs) should be employed to reduce the 
incidence of HCA-CDI.1 Despite HCA-CDI being an outcome measure for ASPs, 
 
 
increasing community acquisition of CDI may cloud interpretation of HCA-CDI 
rates.2 Antimicrobial stewardship (AMS) interventions targeting HCA-CDI have 
predominantly been conducted in metropolitan teaching hospitals, at single sites or 
within a defined clinical area.9-13 Very limited data exist on the burden of HCA-CDI 
in Australia, particularly in regional and rural settings.14 To our knowledge this is the 
first study to examine a multisite ASP in relation to HCA-CDI rates in the non-
metropolitan setting. 
 
The aims of our study were: to describe HCA-CDI rates before and after an ASP; to 
measure LOS and hospital costs in HCA-CDI patients across multiple hospital sites; 
to compare prior antimicrobial and PPI use in HCA-CDI patients with the background 








From December 2010 to April 2016, a comparative before-and-after intervention 
study on the burden of HCA-CDI was performed across the nine public hospitals 
(1000 total beds) of Illawarra Shoalhaven Local Health District (ISLHD) in south 
eastern New South Wales (NSW), Australia. The district services 390,000 residents 
across a catchment that begins one hour south of Sydney, and extends 250km along a 
coastal strip. The three largest hospitals comprise one principal referral hospital (550 
beds), a large acute hospital (150 beds) and a medium acute hospital (100 beds). The 
remaining six hospitals are either small acute or mixed sub- and non-acute.15 This 




In May and June 2012, an ASP supported by a computerised clinical decision support 
system (CDSS; GuidanceMS®17) was uniformly implemented across the district’s 
nine hospitals. In addition to the CDSS, the ASP involved a restriction policy, 
whereby broad spectrum antimicrobials were only stocked in pharmacy (with supply 
contingent on CDSS approval) or specialist areas (i.e. intensive care unit [ICU], 
emergency department, haematology/oncology ward). An education campaign 
 
 
involved regular departmental presentations, and an intranet webpage was established 
to improve access to guidelines. Regular AMS rounds occurred at the three largest 
hospitals, and an antimicrobial advice telephone hotline was established across the 
district to support the smaller hospitals without onsite AMS clinicians. See Figure 1 
for the study flowchart. There were no major changes to infection control policies 
related to either Clostridium difficile or hand hygiene during the study period.  
 
Following a review of HCA-CDI rates, in April 2013 the AMS team (infectious 
diseases doctors and pharmacists) introduced a targeted CDI intervention. The AMS 
pharmacist audited all CDI cases for the following: patient demographics, risk factors, 
antimicrobial treatment, severe disease,3 ICU admission, surgical intervention, and 
NAP1/027 strain. A feedback email was then sent to the attending medical officer 
(AMO) within two weeks (Appendix A). Qualitative analysis of email responses 
determined the level of acceptance by AMOs. Responses were categorised as clinical 
feedback, basic acknowledgment or defensive. The appropriateness of HCA-CDI 
treatment3 was assessed during AMS rounds or retrospectively from medical notes. 
Results were presented to the AMS, drug and therapeutics, and infection control 
committees.  
 
Clostridium difficile laboratory testing 
 
From December 2010, our laboratory protocol subjected all diarrhoeal stools to 
Clostridium difficile testing. First line testing targeted glutamate dehydrogenase 
 
 
(GDH) antigen and toxins A and B (C. Diff Quik Chek Complete®, Techlab, 
Blacksburg, VA, USA). If those tests were discordant, then a polymerase chain 
reaction (PCR; GeneXpert®, Cepheid, Sunnyvale, CA, USA) test was employed, 
which could also detect the NAP1/027 strain.  
 
Effect of HCA-CDI on LOS and hospital costs 
 
LOS and hospital cost analysis was performed only for the three acute hospitals due to 
a shortage of matched controls and other confounders for LOS at smaller hospitals 
(e.g. nursing home availability, social factors). Definitions for HCA-CDI were: HCA-
healthcare facility onset, diarrhoea onset >48 hours after admission; HCA-community 
onset, diarrhoea onset in the community or <48 hours after admission, but within four 
weeks of last discharge.18 Demographic data for HCA-CDI cases did not differ 
significantly between hospitals, or between the two types of HCA-CDI (data not 
shown). 
 
A post hoc analysis of LOS and hospital costs was conducted for those HCA-CDI 
cases identified from 1st April 2013 to 30th April 2014. Matched controls were 
identified from diagnosis-related group (DRG) data19 for HCA-CDI cases (N=103). 
Controls were identified from 1st January 2013 to 30th June 2014. Two controls were 
matched to each case by site, sex, age (+/- 5 years), and DRG (81 cases). Where two 
matched controls were not available, one control was identified (10 cases), resulting 
in 91 cases and 172 controls (Figure 1). DRGs were grouped and the most common 
 
 
DRGs were reported. Additional analysis was performed on those HCA-CDI cases 
and controls with LOS of ≥8 days to address time-dependent biases (8 days equalled 
the median time to HCA-CDI onset). 
 
Antimicrobial and PPI use 
 
Antimicrobial use within one month prior to diagnosis among HCA-CDI patients was 
compared with background antimicrobial use data, regularly collected in Australia as 
part of standard surveillance reports. Those data (defined daily doses [DDDs] per 
1000 occupied bed days [OBDs]) from the three acute hospitals were derived from the 
Australian National Antimicrobial Utilisation Surveillance Program (from pharmacy 
software) and the Australian National Antimicrobial Prescribing Survey (point 
prevalence survey in November 2013, seasonally corrected, antimicrobial class use as 
a percentage of total use). PPI use was also compared with background use (point 




Interrupted time series analysis 20 was used to assess HCA-CDI rates at the three large 
hospitals (due to comparability of acute OBD data). Data were included from 
December 2010 (earliest time point with current CDI testing methods) to April 2016, 
with the intervention point defined as May 2012 (introduction of multisite ASP). 
 
 
Separate analyses were performed for May 2012- Mar 2013 and April 2013 onwards 
(targeted CDI intervention). Since those periods did not reveal any significant 
differences (data not shown) the post-intervention period was reported as one interval. 
A chi-square test was used for proportions or Fisher’s exact test where appropriate. A 
Mann-Whitney U-test was used to compare continuous variables such as LOS and 
hospital costs. Stata® Statistical Software Version 14 was used (Statacorp, College 
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Figure 2 shows interrupted time series analysis of monthly HCA-CDI rates. The 
model-predicted HCA-CDI rate in December 2010 was 3.07 cases/10,000 OBDs. 
Prior to introduction of the ASP, the model-predicted rate was 4.6 cases/10,000 
OBDs. Following ASP’s introduction, and including the targeted email intervention, 
HCA-CDI rates remained stable at 4 cases/10,000 OBDs. None of those differences 
reached statistical significance. Detailed time series data are provided in Appendix B.  
 
During the targeted intervention phase from April 2013 to April 2014, 120 primary 
HCA-CDI cases were identified. The median age was 73 years (interquartile range 
[IQR] 63-81yrs) and 51/120 patients were male (43%). Antimicrobials one month 
prior to HCA-CDI diagnosis were received by 107/120 patients (89%).  Severe 
disease was identified in 8/120 (7%) cases; there were 8/120 (7%) ICU admissions, no 
surgical interventions, and no NAP1/027 strains.  
 
Of the emails sent to AMOs for 120 HCA-CDI cases from April 2013-14, 23 
responses were received (19% response rate). Of those responses, 10 contained 
clinical feedback, 13 contained basic acknowledgement, and there were no defensive 
responses. Examples of clinical feedback responses were: “...in the setting of immune 
suppression and...other complications with chemo I am treating C diff…”;  and, “the 




Median LOS was 11 days greater for HCA-CDI patients (N=91; 17 days [IQR 8-27]) 
than their matched controls (N=172; 6 days [IQR 3-12]; P<0.01). Also, median 
hospital cost was AU$11,361 higher for the HCA-CDI group ($19,222 [IQR $7,817 - 
$41,337]) compared to controls ($7,861 [IQR $3,477 - $14,553]; P<0.01). The 
median time to onset of HCA-CDI was 8 days (IQR 4-14).  
 
The median hospital cost for 48 HCA-CDI patients with LOS ≥ 8 days was 
AU$17,832 (IQR 9,472-28,840) vs. AU$12,563 (9,072-20,086) for 70 controls with 
LOS ≥ 8 days (P=0.17). For patients with LOS ≥ 8 days, the median LOS was 16 days 
(IQR 10-26) for HCA-CDI cases vs. 15 days (IQR 12-26) for controls. After 
excluding non-treated patients (N=6) with available controls (N=11), the difference 
between HCA-CDI patients and controls persisted for median LOS (18 vs. 7 days; 
P<0.01) and cost (AU$20,245 vs. $8,924; P<0.01). The five most common primary 
DRG groups among 263 HCA-CDI cases and controls were: gastrointestinal (N=18 
for cases, N=36 for controls), haematological malignancy (N=9, N=17), orthopaedic 
surgery (N=8, N=15), abdominal surgery (N=6, N=10), and cardiac (N=5, N=9). 
 
Antimicrobial use among the HCA-CDI group at the three acute hospitals was 
compared with background antimicrobial use. Over-represented in HCA-CDI patients 
were third generation cephalosporins (e.g. ceftriaxone; 34% of total use in HCA-CDI 
patients vs. 11% of background use; P<0.01), beta-lactamase inhibitor combinations 
(e.g. piperacillin/tazobactam; 58% vs. 36%; P=0.01), nitroimidazoles (e.g. 
 
 
metronidazole; 28% vs. 11%; P<0.01), and glycopeptides (e.g. vancomycin; 23% vs. 
6%; P<0.01). Under-represented in HCA-CDI patients were beta lactamase resistant 
penicillins (e.g. flucloxacillin; 7% vs. 18%; P=0.02), beta lactamase sensitive 
penicillins (e.g. benzylpenicillin; 2% vs. 9%; P=0.03), extended spectrum penicillins 
(e.g. ampicillin; 14% vs. 33%; P=0.03), macrolides (e.g. azithromycin; 4% vs. 19%; 
P<0.01), and tetracyclines (e.g. doxycycline; 4% vs. 38%; P<0.01). 
 
Vancomycin and metronidazole were over-represented in HCA-CDI patients, but are 
also recommended for CDI treatment. Those two classes were further analysed. For 
vancomycin, the most commonly co-prescribed antimicrobial was 
piperacillin/tazobactam (11/25) with febrile neutropenia the commonest known 
indication (9/11). Vancomycin use was intravenous in all of those cases. For 
metronidazole, the most commonly co-prescribed antimicrobial was ceftriaxone 
(13/35), predominantly for abdominal infections (10/13). There was an overall 
decrease in use of broad spectrum antimicrobials following implementation of the 
multisite ASP (data not shown). PPI use was documented in 83/120 (69%) HCA-CDI 
patients compared with 343/730 (47%) patients audited as part of the local 2013 point 
prevalence survey (P<0.01). 
 
In non-severe HCA-CDI treated at the acute hospitals (N=95), oral metronidazole was 
initiated in 78 (82%) cases. Oral vancomycin plus oral metronidazole was used in 
eight (8%) cases, where metronidazole alone would have sufficed.3 No therapy was 
given in nine non-severe cases, due to cessation of diarrhoea with or without 
identification of an alternative correctable cause. In the severe HCA-CDI group 
 
 
(N=8), oral metronidazole was initiated in 4 (50%) cases, where oral vancomycin, 
intravenous metronidazole or a combination was indicated. In those cases a relevant 





Our study describes the relationship between HCA-CDI rates and a multisite ASP 
supported by a CDSS, education and antimicrobial restriction combined with targeted 
audit and feedback. Implementation of an ASP was temporally associated with stable 
HCA-CDI rates. Targeted interventions may help to combat the waning of the initial 
impact of a program over time. We found that in an Australian non-metropolitan 
setting, LOS and hospital costs were significantly increased in HCA-CDI patients 
when compared with matched controls. Increased antimicrobial and PPI use in 
patients with HCA-CDI were consistent with previous reports.6, 8 Although the initial 
treatment of non-severe HCA-CDI cases predominantly matched guidelines, there 
was concerning use of oral metronidazole in half of the severe cases (albeit with small 
numbers). This was similar to previous findings elsewhere,21 likely resulting from 
under-recognition of severity criteria.3, 22  
 
HCA-CDI has been associated with increased LOS and hospital costs.4 Most studies 
evaluating these effects were either epidemiological studies23, 24 or performed in the 
metropolitan setting.10 To our knowledge this is the first study to combine evaluation 
of the burden of HCA-CDI with multisite ASP implementation in a regional and rural 
setting. Comparison with matched controls11, 25 allowed for a pragmatic approach to 
identifying additional LOS and hospital costs associated with HCA-CDI. For those 
patients with LOS ≥ 8 days, there was a 42% increase in hospital costs in HCA-CDI 
patients compared with controls, despite similar LOS in those groups. This 
 
 
highlighted the increased cost of caring for HCA-CDI patients additional to greater 
LOS, and alleviated the potential for time-dependent biases. 
 
There were several limitations to this study. We included all positive Clostridium 
difficile tests during the targeted intervention phase, as the frequency of daily 
diarrhoeal episodes was unreliably documented. Alternative causes of diarrhoea may 
have been present in some patients carrying Clostridium difficile. We could not 
attribute the increase in LOS and hospital costs to HCA-CDI alone. Alternative 
statistical methods such as multi-state modelling26 to account for time-dependent 
biases, and propensity matching4 to accurately estimate the impacts of CDI have been 
proposed. To account for those limitations, we applied the case-control methodology 
in two additional subsets: the “long-stay” patients (≥8 days, the median time-to-onset 
of HCA-CDI) and only those treated for HCA-CDI. Those results were in line with 
our primary evaluation, emphasising the high LOS and cost burden of HCA-CDI. As 
expected, gastrointestinal DRGs were overrepresented. In some cases the primary 
DRG may have been allocated to gastrointestinal due to CDI severity or duration.  
 
Community cases could not be accurately assessed with the current study resources. 
Of 120 HCA-CDI cases, only 91 were eventually analysed for LOS and cost. 
Assessing the impact on HCA-CDI rates might have been confounded for 
antimicrobials (e.g. metronidazole, vancomycin) often given to treat CDI or co-
administered with antimicrobials associated with HCA-CDI. Intravenous vancomycin 
has been associated with CDI27; however, vancomycin was associated with CDI in 
this study only when combined with other antimicrobials. We did not evaluate 
 
 
appropriateness of prior antimicrobial use, in order to define avoidable HCA-CDI 
cases. Detailed demographic data and prior antimicrobial use were not collected for 
controls, as this dataset was collected to allow for a post hoc analysis. Using 
background antimicrobial and PPI data allowed for larger numbers and accounted for 
the potential of bias due to under-reporting of those agents in control patients in 
whom CDI was not considered. However, detailed characteristics of patients from 
whom the background use data were derived were not available. The largest hospital 
accounted for two thirds of the total OBDs; hence its infection rate largely determined 
the overall rate. The response rate to emails was only 19%, limiting conclusions about 
their impact; however, responses were not requested in the initial email, and still some 
useful clinical feedback was received. Due to the hospitals’ geographic disparity, 
email remained the most pragmatic feedback method. 
  
Patient complexity in our hospitals may be lower compared with larger metropolitan 
hospitals, limiting generalisability to those settings. Further studies combining 
evaluation of ASPs with targeted CDI interventions would be useful, particularly in 
multisite and non-metropolitan settings. In this study we identified high risk 
antimicrobial classes that have formed targets for ongoing AMS activities. 
 
Our study demonstrates the high burden of HCA-CDI in a non-metropolitan setting. 
While it confirms the association between high-risk antimicrobial use and HCA-CDI, 
it also identifies the possibility of under-recognition of CDI severity criteria during 
treatment initiation. Targeted audit and feedback interventions may be a useful way of 
 
 
consolidating the effects of a multisite ASP, contributing to sustainability, which 
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Figure 1: Study flowchart. 
ASP, antimicrobial stewardship program; CDSS, clinical decision support system; 
HCA, healthcare associated; LOS, length of stay; risk factors, anti-peristaltic use, 
gastrointestinal surgery, immunosuppression; PPIs, proton pump inhibitors; HCA-
CDI, healthcare associated Clostridium difficile infection; DRG, diagnosis-related 




Figure 2: HCA-CDI rates for the three acute hospitals in Illawarra Shoalhaven Local 
Health District, Australia from December 2010 to April 2016 
Vertical line, implementation of antimicrobial stewardship program; HCA-CDI, 
healthcare associated Clostridium difficile infection; OBD, occupied bed day.  
 
Appendix A: Exemplar feedback email to admitting medical officer on Clostridium 




As part of routine antimicrobial stewardship activities we are conducting a 




Your patient X (MRN: 111111) was diagnosed with C. diff diarrhoea on dd/mm/yyyy. 
 
Potential risk factors for your patient included: 
 
(As appropriate) 
• Proton pump inhibitor use –  
• Anti-peristaltic use –  
• Prior GI surgery –  
• Immunosuppression –  
• Antimicrobial use within one month prior to diagnosis –  
 
Details of antimicrobial treatment of CDI. 
I’ve attached a copy of the audit form for your information. Please don’t hesitate to 






Appendix B: HCA-CDI rates before and after implementation of an ASP 
 Pre-ASP (Dec 2010 to April 2012) Post-ASP (May 2012 to April 2016) 
Initial level Initial trend p-value Change  
in level 
p-value Change  
in trend 
p-value 








0.24 -0.08a  
(-0.24-0.07) 
0.26 
Initial level, number of cases of HCA-CDI per 10,000 occupied bed days per month; initial trend, rate of increase per month; change in level, 
immediate difference between pre-intervention and post-intervention cases; change in trend, difference between pre-intervention and post-
intervention trend by month; ASP, antimicrobial stewardship program, detail described in Methods; HCA-CDI, healthcare associated 
Clostridium difficile infection, data included for the three large acute hospitals of the health district; OBDs, occupied bed days; LCI, lower 95% 
confidence interval; UCI, upper 95% confidence interval; aadjusted for first order autocorrelation; 
 
